- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00291876
Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine Injected According to a 0, 12-month Schedule
Double-blind Randomized Study to Evaluate the Immunogenicity and Reactogenicity of Two Different Lots of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine Containing 1440 EL.U of Antigen Per mL and Injected According to a 0, 12 Month Schedule in Healthy Adult Volunteers
The aim of this study is to evaluate the persistence of hepatitis A antibodies at 138, 150, 162, 174,186, 198, 210, 222, 234 and 246 months after subjects received their first dose of a 2 dose vaccination schedule of hepatitis A vaccine.
This protocol posting deals with objectives & outcome measures of the extension phase at year 11 to 20.
No additional subjects will be recruited during this long-term follow-up.
연구 개요
상세 설명
This is a long-term follow-up study at Years 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20 after primary vaccination with GSK Biologicals' hepatitis A vaccine (two-dose schedule). To evaluate the long-term antibody persistence, volunteers will donate a blood sample at Years 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20 after the first vaccine dose of the primary vaccination course to determine their anti-hepatitis A (anti-HAV) antibody concentrations.
If a subject has become seronegative for anti-HAV antibodies during any of the long-term blood sampling time point (i.e. Months 138, 150, 162, 174,186, 198, 210, 222, 234 and 246), he/ she will be offered an additional vaccine dose. A blood sample will be taken on the day of the additional vaccination 14 days and one month after additional vaccination to evaluate the immune response following this vaccination.
The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007 and to extend the follow up until Year 20.
The study has 10 phases: 100571, 100572, 100573, 100574, 100575, 110677, 110678, 110679, 110680, 110681.
연구 유형
등록 (실제)
단계
- 4단계
연락처 및 위치
연구 장소
-
-
-
Wilrijk, 벨기에, 2610
- GSK Investigational Site
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Subjects who had received at least one dose of the study vaccine in the primary study
- Written informed consent will have been obtained from the subjects before the blood sampling visit of each year.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Havrix Group
Subjects who received during the primary study 2 doses of Havrix™ at Day 0 and at Month 12.
|
2 doses at 12 months interval
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Anti-hepatitis A Virus (Anti-HAV) Antibody Concentration
기간: At Months 138, 150, 162, 174, 186, 198, 210, 222, 234 and 246
|
Concentrations given as geometric mean concentration (GMC) expressed as milli-international unit per millilitre (mIU/mL).
** = Regarding Month 234 data, please note that there were 5 subjects for whom serum sample tube was broken and thus due to risk of contamination the test were not performed.
Hence these subjects were not included in the LT-ATP cohort for immunogenicity analysis at Month 234.
$ = Regarding Month 246 data, please note there was 1 subject for whom serum sample tube was broken and hence scrapped by laboratory.
Hence this subject was not included in the LT-ATP cohort for immunogenicity analysis at Month 246.
|
At Months 138, 150, 162, 174, 186, 198, 210, 222, 234 and 246
|
Number of Seropositive Subjects Against Hepatitis A Virus
기간: At Months 138, 150, 162, 174, 186, 198, 210, 222, 234 and 246
|
A seropositive subject was a vaccinated subject whose concentrations for antibodies against hepatitis A virus (anti-HAV) were equal or above (>=) the assay cut-off for seropositivity of 15 milli-international units per milliliter (mIU/mL).
** = Regarding Month 234 data, please note that there were 5 subjects for whom serum sample tube was broken and thus due to risk of contamination the test were not performed.
Hence these subjects were not included in the LT-ATP cohort for immunogenicity analysis at Month 234.
$ = Regarding Month 246 data, please note there was 1 subject for whom serum sample tube was broken and hence scrapped by laboratory.
Hence this subject was not included in the LT-ATP cohort for immunogenicity analysis at Month 246.
|
At Months 138, 150, 162, 174, 186, 198, 210, 222, 234 and 246
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Anti-hepatitis A Virus (Anti-HAV) Antibody Concentration
기간: Before additional vaccination, 14 days after additional vaccination and 30 days after additional vaccination
|
Concentrations given as GMC expressed as mIU/mL. 4 subjects received additional vaccination at Month 186 and 1 subject at Month 198. Please note that value 14.9 means <15. |
Before additional vaccination, 14 days after additional vaccination and 30 days after additional vaccination
|
Number of Subjects Reporting Solicited Local Symptoms
기간: During the 4-day (Days 0-3) follow-up period after additional vaccination
|
Solicited local symptoms assessed include pain, redness and swelling.
Additional vaccination was given to 4 subjects at the Month 186 timepoint and to 1 subject at the Month 198 timepoint.
|
During the 4-day (Days 0-3) follow-up period after additional vaccination
|
Number of Subjects Reporting Solicited General Symptoms
기간: During the 4-day (Days 0-3) follow-up period after additional vaccination
|
Solicited general symptoms assessed include fatigue, fever, gastrointestinal symptoms and headache. 4 subjects received additional vaccination at Month 186 and 1 subject at Month 198. |
During the 4-day (Days 0-3) follow-up period after additional vaccination
|
Number of Subjects Reporting Unsolicited Adverse Events (AE)
기간: During the 30-day follow-up period after additional vaccination
|
An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. 4 subjects received additional vaccination at Month 186 and 1 at Month 198. |
During the 30-day follow-up period after additional vaccination
|
Number of Subjects Reporting Serious Adverse Events (SAE) Assessed by the Investigator as Related to Primary Study Vaccination, Procedures or Lack of Vaccine Efficacy
기간: At Months 138, 150, 162, 174, 186, 198, 210, 222, 234 and 246
|
An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above
|
At Months 138, 150, 162, 174, 186, 198, 210, 222, 234 and 246
|
Number of Subjects Reporting Serious Adverse Events (SAE) After Additional Vaccination
기간: During the 30-day follow-up period after additional vaccination
|
An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above. 4 subjects received additional vaccination at Month 186 and 1 at Month 198. |
During the 30-day follow-up period after additional vaccination
|
Number of Subjects Reporting Pregnancies After Additional Vaccination
기간: At Months 186 and 198
|
The number of subjects with outcome of pregnancies reported among subjects who had received the additional vaccination was tabulated.
4 subjects received additional vaccination at Month 186 and 1 subject at Month 198.
|
At Months 186 and 198
|
공동 작업자 및 조사자
스폰서
간행물 및 유용한 링크
일반 간행물
- Van Herck K, Jacquet JM, Van Damme P. Antibody persistence and immune memory in healthy adults following vaccination with a two-dose inactivated hepatitis A vaccine: long-term follow-up at 15 years. J Med Virol. 2011 Nov;83(11):1885-91. doi: 10.1002/jmv.22200. Epub 2011 Aug 23.
- Van Herck K, Crasta PD, Messier M, Hardt K, Van Damme P. Seventeen-year antibody persistence in adults primed with two doses of an inactivated hepatitis A vaccine. Hum Vaccin Immunother. 2012 Mar;8(3):323-7. doi: 10.4161/hv.18617. Epub 2012 Feb 13.
- Agrawal A, Kolhapure S, Andani A, Ota MOC, Badur S, Karkada N, Mitra M. Long-Term Persistence of Antibody Response with Two Doses of Inactivated Hepatitis A Vaccine in Children. Infect Dis Ther. 2020 Dec;9(4):785-796. doi: 10.1007/s40121-020-00311-8. Epub 2020 Jul 24.
- Theeten H, Van Herck K, Van Der Meeren O, Crasta P, Van Damme P, Hens N. Long-term antibody persistence after vaccination with a 2-dose Havrix (inactivated hepatitis A vaccine): 20 years of observed data, and long-term model-based predictions. Vaccine. 2015 Oct 13;33(42):5723-5727. doi: 10.1016/j.vaccine.2015.07.008. Epub 2015 Jul 16.
- Hens N, Habteab Ghebretinsae A, Hardt K, Van Damme P, Van Herck K. Model based estimates of long-term persistence of inactivated hepatitis A vaccine-induced antibodies in adults. Vaccine. 2014 Mar 14;32(13):1507-13. doi: 10.1016/j.vaccine.2013.10.088. Epub 2014 Feb 7.
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 100571 (M138)
- 100572 (M150) (기타 식별자: GSK)
- 100573 (M162) (기타 식별자: GSK)
- 100574 (M174) (기타 식별자: GSK)
- 100575 (M186) (기타 식별자: GSK)
- 110677 (M198) (기타 식별자: GSK)
- 110678 (M210) (기타 식별자: GSK)
- 110679 (기타 식별자: GSK)
- 110680 (기타 식별자: GSK)
- 110681 (기타 식별자: GSK)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
연구 데이터/문서
-
개별 참가자 데이터 세트
정보 식별자: 100571 (M138)정보 댓글: For additional information about this study please refer to the GSK Clinical Study Register. The results of this study 100571 are summarised with studies 100572, 100573, 100574, 100575, 110677, 110678, 110679, 110680, and 110681 on the GSK Clinical Study
-
정보에 입각한 동의서
정보 식별자: 100571 (M138)정보 댓글: For additional information about this study please refer to the GSK Clinical Study Register
-
연구 프로토콜
정보 식별자: 100571 (M138)정보 댓글: For additional information about this study please refer to the GSK Clinical Study Register
-
데이터 세트 사양
정보 식별자: 100571 (M138)정보 댓글: For additional information about this study please refer to the GSK Clinical Study Register
-
임상 연구 보고서
정보 식별자: 100571 (M138)정보 댓글: For additional information about this study please refer to the GSK Clinical Study Register
-
통계 분석 계획
정보 식별자: 100571 (M138)정보 댓글: For additional information about this study please refer to the GSK Clinical Study Register
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
A형 간염에 대한 임상 시험
-
King Saud University완전한
-
Medical University of Vienna완전한
-
Cheikh Anta Diop University, SenegalInternational Atomic Energy Agency아직 모집하지 않음
-
Ionis Pharmaceuticals, Inc.완전한
-
Arab American University (Palestine)완전한
-
Institute of Nutrition of Central America and PanamaBill and Melinda Gates Foundation; Newcastle University; International Atomic Energy Agency완전한
-
University of California, DavisHelen Keller International완전한
Havrix™에 대한 임상 시험
-
GlaxoSmithKline완전한감염, 유두종 바이러스미국, 스페인, 핀란드, 독일, 대만, 벨기에, 필리핀 제도, 캐나다, 호주, 영국, 태국, 브라질, 이탈리아, 멕시코
-
Canadian Immunization Research NetworkUniversity of British Columbia; University of Calgary; Dalhousie University; Université de...완전한
-
GlaxoSmithKline완전한
-
Boryung Biopharma Co., Ltd.아직 모집하지 않음